Table 3 Treatment approach for subsequent therapy in patients after the progression of disease with therapy failure

Disease progression with no previous exposure to anti-angiogenic therapy

VEGFR Inhibitors- Axitinib, Cabozantinib, Sunitinib, Pazopanib, Lenvatinib plus everolimus

Nivolumab plus Ipilimumab if no previous exposure Ipilimumab

Disease progression with VEGFR inhibitor plus immunotherapy

Cabozantinib, Lenvatinib plus everolimus

Disease progression with VEGFR inhibitor without prior exposure to immune checkpoint inhibitors

Nivolumab